Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sigma-Aldrich® Receives National Institutes of Health Funding for Cardiovascular Disease Research

Published: Monday, August 09, 2010
Last Updated: Monday, August 09, 2010
Bookmark and Share
Sigma® Life Science to analyze plasma samples from FHS in researching novel biomarkers for cardiovascular disease.

Sigma-Aldrich® announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI’s Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.

The FHS began in 1948 as a study of more than 5,000 residents of Framingham, Massachusetts, to identify the factors that increase the risk for CVD. Since then, it has expanded to include over 14,000 participants from three generations within families. Using the results of FHS, researchers have identified a host of risk factors, including high blood cholesterol levels, elevated blood pressure, smoking, diabetes and obesity. The FHS is funded by the NHLBI and conducted in collaboration with BU's School of Medicine and School of Public Health.

Sigma® Life Science, a biological products and services business of Sigma-Aldrich, plans to work with NHLBI and BU to provide for the analysis of plasma samples from 7,000 participants to investigate 180 potential biomarkers for CVD. Over the course of this five-year project, Sigma Life Science expects to develop antibody reagents for each identified target biomarker and incorporate the reagents into a multiplexed, high-throughput platform to measure the proteins of interest.

“Through this project, Sigma Life Science, the NHLBI and BU are furthering insight into a number of important CVD targets,” said Dave Smoller, President of Sigma-Aldrich’s Research Biotech Business Unit.”

Smoller  continues, “By embarking on this exciting effort, we believe we will help to develop the next generation of biomarker technologies for life science research and therapeutic applications, and provide greater understanding into the genetics and biological pathways of heart disease. The project is expected to facilitate the development of diagnostic tools for the early detection and prevention of CVD, as well as therapies for early treatment. We are hopeful that establishing valid surrogate biomarkers will also be useful in the development of more individualized treatments for patients. ”

The new project is part of a major FHS initiative called the Systems Approach to Biomarker Research in Cardiovascular Disease (SABRe CVD), which expects to identify and validate new CVD biomarkers, which in turn could ultimately lead to the development of blood tests to identify individuals at high risk of heart disease and stroke.

Only information from FHS participants who have consented to sharing their specimens and data for genetic research will be used, and no shared information will be attributed to a specific participant to protect participants' privacy. Data from these studies will be accessible to other scientists through dbGAP (Database for Genotype and Phenotype), in accordance with data-sharing policies.

“We believe this research will accelerate the development of new diagnostics and treatments for common life-threatening conditions,” said Karen Antman, M.D., Dean of Boston University School of Medicine. “Our faculty takes great pride in being part of this exciting research which may improve the lives of millions of people globally for the better,” she added.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sigma-Aldrich to Restructure Business into Three New Units
Sigma-Aldrich has provided the first details of a major restructuring that will align its organisation into three customer and market-focused business units.
Thursday, November 22, 2012
Sigma-Aldrich Acquires ChemNavigator to Provide Researchers with Chemical Compound Selection and Procurement Services
Deal combines ChemNavigator's database of chemical compounds and cheminformatics tools with chemical services of Sigma-Aldrich.
Friday, August 07, 2009
Sigma-Aldrich Signs Exclusive Agreement with IsoSciences to Distribute Isotopically Labeled Bioactive Compounds
Under the terms of the agreement, IsoSciences will be the exclusive provider to Aldrich for their stable isotope products listed in the agreement for metabolic research.
Friday, September 12, 2008
Scientific News
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Can Cell Cycle Protein Prevent or Kill Breast Cancer Tumors?
An MD Anderson study has shown the potential of a simple molecule involved in cancer metabolism as a powerful therapeutic.
Study Reveals Improved Way to Interpret High-Throughput Biological Data
A recent study has revealed a novel workflow, identifying associations between molecules to provide insights into cellular metabolism and gene expression in complex biological systems.
Optical 'Dog's Nose' Developed to Detect Cancer, Other Diseases
Researchers are using optical spectroscopy to develop a quick, non-invasive “breath test” they believe will have the potential to screen for a variety of diseases, including diabetes, infections and cancers.
Researchers Link Liver Disease and Drug Metabolism
Researchers have discovered that nonalcoholic steatohepatitis, an increasingly common but often undiagnosed liver disease, could have significant medical implications for people with type 2 diabetes.
Scientists Create Synthetic Membranes That Grow Like Living Cells
Chemists and biologists at UC San Diego have succeeded in designing and synthesizing an artificial cell membrane capable of sustaining continual growth, just like a living cell.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Team Led by TSRI Scientists Shows AIDS Vaccine Candidate Successfully ‘Primes’ Immune System
New research shows that an experimental vaccine candidate can stimulate immune activity necessary to prevent HIV infection.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!